Shilpa Medicare’s Bengaluru unit clears USFDA remote record review

29 Jul 2022 Evaluate

Shilpa Medicare’s Unit III, Advanced Analytical Characterization Laboratory situated at Dabaspet, Bengaluru in Karnataka has cleared US Food & Drug Administration (USFDA) remote record review without any objectionable conditions or observations. The review was conducted during November 15 to 18, 2021.

The facility is designed with advanced analytical equipment to provide testing services such as /n-vitro Permeation testing, Nitrosamine testing, Elemental Impurity testing, Extractable & Leachable testing, Glass Delamination testing etc.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

323.70 9.05 (2.88%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×